12:00 AM
 | 
Dec 21, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 12/18 cls
Addex Pharmaceuticals Ltd. (SIX:ADXN) Jefferies Peter Welford Rating change Hold -60% CHF15.70
Welford moved his rating from "under review" to "hold" and set a target of CHF18. He believes Addex has limited catalysts after it discontinued development of ADX10059 for chronic indications, including long-term treatment of gastroesophageal reflux disease (GERD) and migraine prophylaxis. Data from a Phase IIb trial showed 6% of patients given the negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) had alanine transaminase (ALT) levels greater than five times the upper limit of normal (see B15).
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Price target Market outperform 1% $37.64
Raymond lowered his target to $55 from $60 after a survey of nephrologists showed...

Read the full 949 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >